Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicotine patch safe during pregnancy

This article was originally published in The Tan Sheet

Executive Summary

Long-term nicotine replacement therapy advocated for pregnant women otherwise unable to stop smoking by Paul Ogburn, MD, State University of New York at Stony Brook, et al. Researchers found 22 mg/24 hrs of transdermal nicotine therapy administered for eight weeks did not affect gestational age, birth weight or "fetal well-being" in cohort of 21 pregnant smokers. Study was presented at Society for Maternal-Fetal Medicine's annual meeting in New Orleans Jan. 17 and published in December American Journal of Obstetrics & Gynecology. A California judge ruled last March against requiring that nonprescription NRT products carry labeling stating they "can harm your baby" (1"The Tan Sheet" March 26, 2001, p. 21)...

You may also be interested in...

Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris: Customer Dialogue Has Changed From Price, Price, Price To Availability

Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts